HCP
CRSP icon

Hexagon Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Hexagon Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$851 – 432
2025
Q1 		$851 Buy
25
+9
+56% +$382 ﹤0.01% 1578
2024
Q4 		$630 Buy
16
+14
+700% +$661 ﹤0.01% 1661
2024
Q3 		$94 Buy
+2
New +$101 ﹤0.01% 1541
2023
Q1 		– Sell
-1
Closed -$41 – 1462
2022
Q4 		$41 Sell
1
-12
-92% -$637 ﹤0.01% 1437
2022
Q3 		$1K Buy
13
+12
+1,200% +$870 ﹤0.01% 1189
2022
Q2 		$0 Buy
+1
New +$59 ﹤0.01% 1185

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hexagon Capital Partners's CRSP Position: Q2 2025 in Review

Hexagon Capital Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 25 shares — an estimated $851 sold.

Hexagon Capital Partners first reported a position in CRSP in Q2 2022 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Hexagon Capital Partners reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 25 CRISPR Therapeutics shares in Q2 2025, an estimated $851.
  • Hexagon Capital Partners first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 6 quarters.
  • Hexagon Capital Partners's CRISPR Therapeutics position peaked at $1K in Q3 2022.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.